About Arrowhead Pharmaceuticals (NASDAQ:ARWR)
Arrowhead Pharmaceuticals, Inc., formerly Arrowhead Research Corporation, develops medicines that treat intractable diseases by silencing the genes that cause them. Using a portfolio of ribonucleic acid (RNA) chemistries and modes of delivery, the Company's therapies trigger the RNA interference mechanism to induce knockdown of target genes. The Company is focused on developing drugs for diseases with a genetic basis, characterized by the overproduction of one or more proteins. The Company's preclinical pipeline of RNA interference (RNAi) therapeutics includes both subcutaneously administered liver-targeted candidates and extra-hepatic candidates. The Company's pre-clinical-stage drug candidates include ARO-HBV, ARO-AAT, ARO-LPA, ARO-AMG1, ARO-F12 and ARO-HIF2. ARO-HBV is an RNAi therapeutic candidate for the treatment of chronic hepatitis B infection. ARO-AAT is a therapeutic candidate for the treatment of liver disease associated with Alpha-1 Antitrypsin Deficiency.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Bio Therapeutic Drugs
- Sub-Industry: N/A
- Symbol: NASDAQ:ARWR
- CUSIP: N/A
- Web: www.arrowheadpharma.com
Capitalization:- Market Cap: $290.86 million
- Outstanding Shares: 74,772,000
Average Prices:- 50 Day Moving Avg: $3.77
- 200 Day Moving Avg: $2.25
- 52 Week Range: $1.20 - $6.86
P/E:- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -5.89
- P/E Growth: -1.30
Sales & Book Value:- Annual Revenue: $22.73 million
- Price / Sales: 12.80
- Book Value: $1.21 per share
- Price / Book: 3.21
Profitability:- EBITDA: ($47,970,000.00)
- Net Margins: -201.84%
- Return on Equity: -46.73%
- Return on Assets: -34.08%
Debt:- Debt-to-Equity Ratio: 0.03%
- Current Ratio: 3.84%
- Quick Ratio: 3.84%
Misc:- Average Volume: 1.24 million shs.
- Beta: 1.94
- Short Ratio: 10.59
Frequently Asked Questions for Arrowhead Pharmaceuticals (NASDAQ:ARWR)
What is Arrowhead Pharmaceuticals' stock symbol?
Arrowhead Pharmaceuticals trades on the NASDAQ under the ticker symbol "ARWR."
How were Arrowhead Pharmaceuticals' earnings last quarter?
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) posted its earnings results on Thursday, August, 3rd. The company reported ($0.07) EPS for the quarter, topping analysts' consensus estimates of ($0.13) by $0.06. The firm earned $9.34 million during the quarter, compared to analysts' expectations of $5.29 million. Arrowhead Pharmaceuticals had a negative net margin of 201.84% and a negative return on equity of 46.73%. View Arrowhead Pharmaceuticals' Earnings History.
When will Arrowhead Pharmaceuticals make its next earnings announcement?
Where is Arrowhead Pharmaceuticals' stock going? Where will Arrowhead Pharmaceuticals' stock price be in 2017?
5 brokers have issued 1 year price objectives for Arrowhead Pharmaceuticals' shares. Their forecasts range from $2.00 to $2.00. On average, they anticipate Arrowhead Pharmaceuticals' share price to reach $2.00 in the next twelve months. View Analyst Ratings for Arrowhead Pharmaceuticals.
Who are some of Arrowhead Pharmaceuticals' key competitors?
Some companies that are related to Arrowhead Pharmaceuticals include Madrigal Pharmaceuticals (MDGL), Calithera Biosciences (CALA), Achaogen (AKAO), Achillion Pharmaceuticals (ACHN), Insys Therapeutics (INSY), Nightstar Therapeutics PLC (NITE), Aurinia Pharmaceuticals (AUPH), Karyopharm Therapeutics (KPTI), Clementia Pharmaceuticals (CMTA), Jounce Therapeutics (JNCE), uniQure N.V. (QURE), Sucampo Pharmaceuticals (SCMP), Rigel Pharmaceuticals (RIGL), Progenics Pharmaceuticals (PGNX), Selecta Biosciences (SELB), NuCana PLC (NCNA), Atara Biotherapeutics (ATRA) and Mersana Therapeutics (MRSN).
Who are Arrowhead Pharmaceuticals' key executives?
Arrowhead Pharmaceuticals' management team includes the folowing people:
- Douglass B. Given M.D., Ph.D., Chairman of the Board
- Christopher Richard Anzalone Ph.D., President, Chief Executive Officer, Director
- Kenneth Allen Myszkowski, Chief Financial Officer
- Bruce D. Given M.D., Chief Operating Officer
- Patrick O'Brien, General Counsel
- Michael S. Perry Ph.D., Lead Independent Director
- Mauro Ferrari Ph.D., Independent Director
- Edward W. Frykman, Independent Director
How do I buy Arrowhead Pharmaceuticals stock?
Shares of Arrowhead Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Arrowhead Pharmaceuticals' stock price today?
One share of Arrowhead Pharmaceuticals stock can currently be purchased for approximately $3.89.
MarketBeat Community Rating for Arrowhead Pharmaceuticals (NASDAQ ARWR)MarketBeat's community ratings are surveys of what our community members think about Arrowhead Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Consensus Ratings for Arrowhead Pharmaceuticals (NASDAQ:ARWR) (How are Consensus Ratings Calculated?) MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
| Ratings Breakdown: | 4 Hold Ratings, 1 Buy Rating |
| Consensus Rating: | Hold (Score: 2.20) |
| Consensus Price Target: | $2.00 (48.59% downside) |
Consensus Price Target History for Arrowhead Pharmaceuticals (NASDAQ:ARWR)
Analysts' Ratings History for Arrowhead Pharmaceuticals (NASDAQ:ARWR)
Show:
| Date | Firm | Action | Rating | Price Target | Impact on Share Price | Details |
|---|
| 9/25/2017 | Cantor Fitzgerald | Reiterated Rating | Hold | $2.00 | Medium |  |
| 9/18/2017 | William Blair | Upgrade | Market Perform -> Outperform | | High | |
| 9/13/2017 | Chardan Capital | Reiterated Rating | Neutral | | Medium | |
| 8/4/2017 | Jefferies Group LLC | Reiterated Rating | Hold | $2.00 | High | |
| 7/28/2017 | Piper Jaffray Companies | Reiterated Rating | Hold | $2.00 | Medium | |
(Data available from 10/23/2015 forward)
Earnings History for Arrowhead Pharmaceuticals (NASDAQ:ARWR)Earnings History by Quarter for Arrowhead Pharmaceuticals (NASDAQ ARWR)| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 12/12/2017 | | ($0.10) | | | | | N/A | |
| 8/3/2017 | Q3 2017 | ($0.13) | ($0.07) | $5.29 million | $9.34 million | View | Listen | |
| 5/3/2017 | Q2 2017 | ($0.12) | ($0.08) | $4.19 million | $8.99 million | View | Listen | |
| 2/6/2017 | Q117 | ($0.20) | ($0.17) | $13.24 million | $4.37 million | View | Listen | |
| 8/9/2016 | Q316 | ($0.37) | ($0.32) | $0.05 million | $39.58 million | View | N/A | |
| 5/10/2016 | Q216 | ($0.37) | ($0.35) | $0.26 million | $0.04 million | View | Listen | |
| 2/9/2016 | Q1 | ($0.41) | ($0.32) | $0.29 million | $0.04 million | View | N/A | |
| 12/14/2015 | Q415 | ($0.39) | ($0.42) | $0.14 million | $0.04 million | View | Listen | |
| 8/4/2015 | Q315 | ($0.38) | ($0.27) | $0.11 million | $0.12 million | View | N/A | |
| 5/11/2015 | Q214 | ($0.35) | ($0.33) | $110.00 million | $43.75 million | View | Listen | |
| 2/9/2015 | Q114 | ($0.32) | ($0.41) | $0.24 million | $0.17 million | View | N/A | |
| 11/25/2014 | Q413 | ($0.25) | ($0.33) | $0.04 million | $0.04 million | View | N/A | |
| 8/12/2014 | Q313 | ($0.22) | ($0.22) | $0.04 million | $0.04 million | View | N/A | |
| 5/6/2014 | Q2 2014 | ($0.18) | ($0.31) | $0.05 million | $0.04 million | View | N/A | |
| 2/4/2014 | Q4 | ($0.18) | ($0.33) | | | View | N/A | |
| 12/18/2013 | Q4 | ($0.23) | ($0.43) | | | View | Listen | |
| 5/9/2013 | Q2 2013 | | ($0.41) | | | View | N/A | |
| 2/13/2013 | Q1 2013 | | ($0.33) | | | View | N/A | |
| 12/20/2012 | Q4 2012 | | ($0.43) | | | View | N/A | |
(Data available from 1/1/2011 forward)
Earnings Estimates for Arrowhead Pharmaceuticals (NASDAQ:ARWR)2017 EPS Consensus Estimate: ($0.21)
2018 EPS Consensus Estimate: ($0.68)
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|
| Q1 2017 | 1 | $0.22 | $0.22 | $0.22 |
| Q2 2017 | 2 | ($0.16) | ($0.11) | ($0.14) |
| Q3 2017 | 3 | ($0.15) | ($0.13) | ($0.14) |
| Q4 2017 | 3 | ($0.18) | ($0.10) | ($0.15) |
| Q1 2018 | 1 | ($0.11) | ($0.11) | ($0.11) |
| Q2 2018 | 1 | ($0.19) | ($0.19) | ($0.19) |
| Q3 2018 | 1 | ($0.19) | ($0.19) | ($0.19) |
| Q4 2018 | 1 | ($0.19) | ($0.19) | ($0.19) |
(Data provided by Zacks Investment Research)
Dividend History for Arrowhead Pharmaceuticals (NASDAQ:ARWR)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Arrowhead Pharmaceuticals (NASDAQ:ARWR)Insider Ownership Percentage: 4.57%
Institutional Ownership Percentage: 20.61%
Insider Trades by Quarter for Arrowhead Pharmaceuticals (NASDAQ:ARWR)| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Details |
|---|
| 10/14/2016 | Douglas B. Given | Director | Sell | 12,000 | $6.72 | $80,640.00 | |
| 8/23/2016 | Kenneth Allen Myszkowski | CFO | Sell | 6,900 | $8.00 | $55,200.00 | |
| 8/22/2016 | Kenneth Allen Myszkowski | CFO | Sell | 13,100 | $8.00 | $104,800.00 | |
| 12/30/2015 | Kenneth Allen Myszkowski | CFO | Sell | 23,347 | $6.13 | $143,117.11 | |
| 10/28/2015 | Mauro Ferrari | Director | Buy | 400 | $7.62 | $3,048.00 | |
| 10/9/2015 | Mauro Ferrari | Director | Buy | 1,900 | $6.19 | $11,761.00 | |
| 1/5/2015 | David L Lewis | Insider | Sell | 15,000 | $8.01 | $120,150.00 | |
| 10/15/2014 | Christopher Richard Anzalone | CEO | Buy | 16,000 | $6.32 | $101,120.00 | |
| 10/1/2014 | Charles Mckenney | Director | Sell | 2,500 | $14.70 | $36,750.00 | |
| 9/30/2014 | David L Lewis | Insider | Sell | 15,000 | $15.02 | $225,300.00 | |
| 9/26/2014 | Douglas B Given | Director | Sell | 2,000 | $15.24 | $30,480.00 | |
| 6/9/2014 | Charles Mckenney | Director | Sell | 22,000 | $14.32 | $315,040.00 | |
| 2/12/2014 | Kenneth Allen Myszkowski | CFO | Sell | 16,000 | $18.77 | $300,320.00 | |
| 2/7/2014 | Edward W Frykman | Director | Sell | 3,148 | $15.98 | $50,305.04 | |
(Data available from 1/1/2013 forward)
Headline Trends for Arrowhead Pharmaceuticals (NASDAQ:ARWR)
Latest Headlines for Arrowhead Pharmaceuticals (NASDAQ:ARWR)
| Source: |
|
Loading headlines, please wait.
Arrowhead Pharmaceuticals (ARWR) Chart for Monday, October, 23, 2017
